Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Ingelheim, Germany and South San Francisco, Calif., USA — 4 January 2023 — Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies. Despite the significant transformation of the cancer treatment landscape… The post Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies first appeared on 3T Biosciences .